Rokit to launch what it calls first human kidney regeneration surgery in July

ROKIT to launch what it calls 1st human kidney regeneration surgery in July

잠깐! 현재 Internet Explorer 8이하 버전을 이용중이십니다. 최신 브라우저(Browser) 사용을 권장드립니다!

인터넷 익스플로러 11 다운로드

chrome

구글 크롬 다운로드

firefox

모질라 파이어폭스 다운로드

본문영역

이전 기사보기 다음 기사보기

ROKIT to launch what it calls 1st human kidney regeneration surgery in July

바로가기 복사하기 본문 글씨 줄이기 본문 글씨 키우기

스크롤 이동 상태바

ROKIT to launch what it calls 1st human kidney regeneration surgery in July

기자명 Kim Ji-hye

Published 2026.06.12 18:22

Comments 0 -->

바로가기 복사하기 본문 글씨 줄이기 본문 글씨 키우기

SNS 기사보내기

Facebook(으)로 기사보내기

Twitter(으)로 기사보내기

Kakaostory(으)로 기사보내기

Copy url(으)로 기사보내기

이메일(으)로 기사보내기 다른 공유 찾기 기사스크랩하기

I share this article

Facebook(으)로 기사보내기

Twitter(으)로 기사보내기

Kakaostory(으)로 기사보내기

Copy url(으)로 기사보내기

닫기

(Courtesy of ROKIT HEALTHCARE)

ROKIT HEALTHCARE said it will begin what it described as the “world’s first” human kidney regeneration surgery in July, after securing approval in Korea for an advanced regenerative medicine (RM) clinical trial (CT).

The study will evaluate the safety and regenerative potential of the company's autologous omental patch technology in humans, according to the company.

ROKIT said the procedure combines AI-based three-dimensional bioprinting (3DBP) with robotic surgery. The company plans to seek advanced RM treatment approval in the fourth quarter.

The company cited preclinical data showing a 63 percent kidney regeneration rate (RR) and said it holds kidney regeneration-related patents in Korea, the U.S. and Japan.

ROKIT is positioning the program for chronic kidney disease (CKD) patients, including through potential medical tourism in the U.S., Europe, the Middle East (ME) and Japan.

Rokit Healthcare enters Saudi market with AI kidney disease prediction deal

ROKIT HEALTHCARE’s US unit files for Nasdaq IPO

ROKIT Healthcare signs MOU with UAE’s MIG for $20M investment and JV

ROKIT Healthcare signs Greece export deal with Cigalah, shipments set for April

ROKIT Healthcare inks US licensing deal for AI kidney function prediction tool with 18% royalty

ROKIT Healthcare partners with Harvard researcher to validate kidney regeneration platform

ROKIT America moves closer to Nasdaq listing after SEC clears registration statement

Kim Ji-hye jkim404@docdocdoc.co.kr

See Other Articles

BTS' Suga-backed center expands autism therapy from music to basketball

[Interview] New KASL hepatitis B guideline shifts focus to HBV DNA, but reimbursement lags

Keytruda expands indications to bladder and ovarian cancers, broadening treatment options

AIRS Medical cut its US team amid a major deal and new funding, ex-staffers say

Novo Holdings courts Korea while channeling investments through Singapore

FDA decision on HLB liver cancer combo delayed, again, over Hengrui plant issues

Kolon Life Science seeks Greater China partners for TG-C at BIO Asia-Taiwan 2026

BTS' Suga-backed center expands autism therapy from music to basketball

댓글 내용입력

Password

닫기

Text

/ 400

Password

닫기

My comment collection

닫기

Top-five global pharma signs deal to test Kangstem’s hair follicle organoids for hair-loss drugs

Praser Therapeutics raises ₩50 billion in pre-IPO funding

Meninblox partners with Estonia's Metrosert to validate AI running companion

MFDS expands Imdelltra use to second-line small cell lung cancer

Why apple cider vinegar doesn't work the same for everyone

Samsung Bioepis, Organon expand biosimilar partnership in Australia